Please ensure Javascript is enabled for purposes of website accessibility

How Bristol-Myers Squibb Company Fell $18.8 Billion in October

By Cory Renauer - Nov 11, 2018 at 8:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A failed clinical trial doesn't bode well for the big pharma's lung cancer strategy.

What happened

Shares of Bristol-Myers Squibb Company (BMY -1.22%), one of America's largest pharmaceutical companies, fell 18.6% in October, according to data from S&P Global Market Intelligence. Bristol's lead drug failed during a clinical trial with small-cell lung cancer patients, and that failure, combined with a dismal month for biotech overall, incited investors to pummel the stock to its lowest level since January 2017.

So what 

The Nasdaq biotechnology index fell a stunning 14.6% in October. While losses this size aren't uncommon for smaller biotechs, Bristol-Myers boasted a $101 billion market cap at the end of September that was cut down as investors worry about the company's lead growth driver, Opdivo. The checkpoint inhibitor earned FDA approval to treat third-line small-cell lung cancer patients based on tumor responses but flopped during the confirmatory study, which was looking for a survival benefit over standard chemotherapy.

A man's glasses fly off his face as a fist punches him.

Image source: Getty Images.

Bristol investors had been hoping Opdivo could earn an expansion to the much larger population of newly diagnosed small-cell lung cancer patients. In September, a similar treatment from Roche (RHHBY 1.09%), called Tecentriq, became the first new therapy to outperform standard care in terms of progression-free survival.

Now what

Using results from very different patient populations is a bit like comparing apples to oranges. That said, it looks as if Tecentriq is going to eat Bristol's lunch in the first-line small-cell lung cancer indication. At an interim observation, a majority of patients receiving Tecentriq in addition to standard care survived 18.1 months, which was 33% longer than standard care on its own. That wasn't strong enough to be considered statistically significant, but the IMpower132 study isn't finished.

Roche will present final results next year, but Tecentriq might not be the last of Bristol's problems when it comes to advancing Opdivo to the first-line small-cell lung cancer setting. Merck & Co. expects to report top-line results from Keytruda's Keynote-064 study in January, and AstraZeneca's Caspian study with Imfinzi should have data ready to present a couple of months later.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$77.74 (-1.22%) $0.96
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$92.51 (0.68%) $0.62
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.81 (1.09%) $0.45
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$67.02 (1.65%) $1.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.